Lataa...
Ruxolitinib for the Treatment of Essential Thrombocythemia
Deregulated Janus Kinase 2 (JAK2) activation is central to the pathogenesis of most myeloproliferative neoplasms (MPNs), of which essential thrombocythemia (ET) is the most common entity. Patients with ET are risk-stratified according to their risk of thrombo-hemorrhagic complications. High-risk pat...
Tallennettuna:
| Julkaisussa: | Hemasphere |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Wolters Kluwer Health
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6746005/ https://ncbi.nlm.nih.gov/pubmed/31723782 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000056 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|